Exelixis | EXEL - 운영 비용





운영 비용 변화 날짜
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bayer EUR 9.88B 452M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
Eisai JPY 215.74B 15.84B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Exelixis USD 359.47M 3.28M 2026-03
Genmab DKK 798M 235M 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sanofi EUR 10.71B 1.32B 2025-12
Takeda JPY 1.11T 85.29B 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Xencor USD 82.38M 513K 2026-03